• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卫生经济学和卫生技术评估中的成本、背景和决策。

COST, CONTEXT, AND DECISIONS IN HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT.

机构信息

University of York - Economics & Related

出版信息

Int J Technol Assess Health Care. 2018 Jan;34(5):434-441. doi: 10.1017/S0266462318000612. Epub 2018 Oct 17.

DOI:10.1017/S0266462318000612
PMID:30326982
Abstract

OBJECTIVES

This study is an attempt to demystify and clarify the idea of cost in health economics and health technology assessment (HTA).

METHODS

Its method draws on standard concepts in economics. Cost is a more elusive concept than is commonly thought and can be particularly elusive in multidisciplinary territory like HTA.

RESULTS

The article explains that cost is more completely defined as opportunity cost, why cost is necessarily associated with a decision, and that it will always vary according to the context of that decision: whether choice is about inputs or outputs, what the alternatives are, the timing of the consequences of the decision, the nature of the commitment to which a decision maker is committed, who the decision maker is, and the constraints and discretion limiting or liberating the decision maker. Distinctions between short and long runs and between fixed and variable inputs are matters of choice, not technology, and are similarly context-dependent. Harms or negative consequences are, in general, not costs. Whether so-called "clinically unrelated" future costs and benefits should be counted in current decisions again depends on context.

CONCLUSIONS

The costs of entire health programs are context-dependent, relating to planned rates of activity, volumes, and timings. The implications for the methods of HTA are different in the contexts of low- and middle-income countries compared with high-income countries, and further differ contextually according to the budget constraints (fixed or variable) facing decision makers.

摘要

目的

本研究试图阐明和澄清卫生经济学和卫生技术评估(HTA)中成本的概念。

方法

其方法借鉴了经济学中的标准概念。与人们普遍认为的相反,成本是一个比想象中更难以捉摸的概念,在 HTA 等多学科领域尤其难以捉摸。

结果

本文解释了成本更完整的定义为机会成本,为什么成本必然与决策相关,并且根据决策的上下文,成本将始终有所不同:无论是关于投入还是产出的选择,替代方案是什么,决策后果的时间,决策者承诺的承诺的性质,决策者是谁以及限制或释放决策者的约束和酌处权。短期和长期之间以及固定投入和可变投入之间的区别是选择的问题,而不是技术,同样取决于上下文。危害或负面后果通常不是成本。在当前决策中是否应考虑所谓的“临床无关”未来成本和收益再次取决于上下文。

结论

整个卫生计划的成本取决于计划的活动、数量和时间的发生频率。这对中低收入国家与高收入国家的 HTA 方法产生了不同的影响,并且根据决策者面临的预算限制(固定或可变)进一步根据上下文而有所不同。

相似文献

1
COST, CONTEXT, AND DECISIONS IN HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT.卫生经济学和卫生技术评估中的成本、背景和决策。
Int J Technol Assess Health Care. 2018 Jan;34(5):434-441. doi: 10.1017/S0266462318000612. Epub 2018 Oct 17.
2
Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.与预算限制和重新分配限制相关的成本效益分析。
Health Policy. 2005 Oct;74(2):146-56. doi: 10.1016/j.healthpol.2004.12.015. Epub 2005 Jan 26.
3
Budget impact analysis.预算影响分析。
J Med Assoc Thai. 2014 May;97 Suppl 5:S65-71.
4
Health technology assessment.卫生技术评估
Q J Nucl Med. 2000 Jun;44(2):105-11.
5
IMPACT OF HEALTH TECHNOLOGY ASSESSMENT REPORTS ON HOSPITAL DECISION MAKERS - 10-YEAR INSIGHT FROM A HOSPITAL UNIT IN SHERBROOKE, CANADA: IMPACT OF HEALTH TECHNOLOGY ASSESSMENT ON HOSPITAL DECISIONS.卫生技术评估报告对医院决策者的影响——来自加拿大舍布鲁克一家医院的 10 年洞察:卫生技术评估对医院决策的影响。
Int J Technol Assess Health Care. 2018 Jan;34(4):393-399. doi: 10.1017/S0266462318000405. Epub 2018 Jul 19.
6
Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].目标、预算、阈值与机会成本——一种卫生经济学方法:一份药物经济学与结果研究协会(ISPOR)特别工作组报告[4]
Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.
7
EMERGENCE OF "DRIVERS" FOR THE IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT.卫生技术评估实施中“驱动因素”的出现
Int J Technol Assess Health Care. 2016 Jan;32(4):300-306. doi: 10.1017/S0266462316000404. Epub 2016 Oct 3.
8
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会(ISPOR)特别工作组报告的总结与建议[7]
Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.
9
Defining the scope of health technology assessment and types of health economic evaluation.界定卫生技术评估的范围及卫生经济评估的类型。
J Med Assoc Thai. 2014 May;97 Suppl 5:S10-6.
10
[Health economics and HTA].[卫生经济学与卫生技术评估]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Mar;49(3):257-63. doi: 10.1007/s00103-005-1228-x.

引用本文的文献

1
Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.估算西班牙国民健康服务体系产生的每质量调整生命年的增量成本:一种固定效应计量经济学方法。
Pharmacoeconomics. 2025 Jan;43(1):109-122. doi: 10.1007/s40273-024-01441-4. Epub 2024 Oct 25.
2
What are economic costs and when should they be used in health economic studies?什么是经济成本,以及它们应在何时用于卫生经济学研究?
Cost Eff Resour Alloc. 2023 May 15;21(1):31. doi: 10.1186/s12962-023-00436-w.
3
The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.
更广泛成本效益分析框架中的更广泛机会成本。
Appl Health Econ Health Policy. 2023 May;21(3):373-384. doi: 10.1007/s40258-023-00801-z. Epub 2023 Apr 12.
4
The ethics of aggregation in cost-effectiveness analysis or, "on books, bookshelves, and budget impact".成本效益分析中的汇总伦理,或“关于书籍、书架与预算影响”
Front Health Serv. 2022 Oct 13;2:889423. doi: 10.3389/frhs.2022.889423. eCollection 2022.
5
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.供给侧成本效益阈值:循证政策的问题。
Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7.
6
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.成本及其来源:确定法国、德国和意大利糖尿病卫生经济评价的单位成本。
Eur J Health Econ. 2020 Nov;21(8):1179-1196. doi: 10.1007/s10198-020-01229-1. Epub 2020 Oct 6.
7
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.针对非随机干预性研究(包括服务评估)进行性价比分析:教育评论及建议。
Pharmacoeconomics. 2020 Jul;38(7):665-681. doi: 10.1007/s40273-020-00907-5.
8
Patients' out-of-pocket expenses analysis of presurgical teledermatology.术前远程皮肤病学患者自付费用分析
Cost Eff Resour Alloc. 2019 Aug 23;17:18. doi: 10.1186/s12962-019-0186-3. eCollection 2019.
9
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.纳入未来医疗成本:对癌症患者成本效益分析的影响。
Pharmacoeconomics. 2019 Jul;37(7):931-941. doi: 10.1007/s40273-019-00790-9.